Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 20

1.

Bifunctional polymeric inhibitors of human influenza A viruses.

Haldar J, Alvarez de Cienfuegos L, Tumpey TM, Gubareva LV, Chen J, Klibanov AM.

Pharm Res. 2010 Feb;27(2):259-63. doi: 10.1007/s11095-009-0013-1. Epub 2009 Dec 15.

2.

CS-8958, a prodrug of the novel neuraminidase inhibitor R-125489, demonstrates a favorable long-retention profile in the mouse respiratory tract.

Koyama K, Takahashi M, Oitate M, Nakai N, Takakusa H, Miura S, Okazaki O.

Antimicrob Agents Chemother. 2009 Nov;53(11):4845-51. doi: 10.1128/AAC.00731-09. Epub 2009 Aug 17.

3.

CS-8958, a prodrug of the new neuraminidase inhibitor R-125489, shows long-acting anti-influenza virus activity.

Yamashita M, Tomozawa T, Kakuta M, Tokumitsu A, Nasu H, Kubo S.

Antimicrob Agents Chemother. 2009 Jan;53(1):186-92. doi: 10.1128/AAC.00333-08. Epub 2008 Oct 27.

4.

Design of multi-binding-site inhibitors, ligand efficiency, and consensus screening of avian influenza H5N1 wild-type neuraminidase and of the oseltamivir-resistant H274Y variant.

García-Sosa AT, Sild S, Maran U.

J Chem Inf Model. 2008 Oct;48(10):2074-80. doi: 10.1021/ci800242z. Epub 2008 Oct 11.

PMID:
18847186
5.

Oseltamivir resistance--disabling our influenza defenses.

Moscona A.

N Engl J Med. 2005 Dec 22;353(25):2633-6. No abstract available.

6.

Susceptibilities of antiviral-resistant influenza viruses to novel neuraminidase inhibitors.

Mishin VP, Hayden FG, Gubareva LV.

Antimicrob Agents Chemother. 2005 Nov;49(11):4515-20.

7.

Potent and long-acting dimeric inhibitors of influenza virus neuraminidase are effective at a once-weekly dosing regimen.

Macdonald SJ, Watson KG, Cameron R, Chalmers DK, Demaine DA, Fenton RJ, Gower D, Hamblin JN, Hamilton S, Hart GJ, Inglis GG, Jin B, Jones HT, McConnell DB, Mason AM, Nguyen V, Owens IJ, Parry N, Reece PA, Shanahan SE, Smith D, Wu WY, Tucker SP.

Antimicrob Agents Chemother. 2004 Dec;48(12):4542-9.

8.

Neuraminidase is important for the initiation of influenza virus infection in human airway epithelium.

Matrosovich MN, Matrosovich TY, Gray T, Roberts NA, Klenk HD.

J Virol. 2004 Nov;78(22):12665-7.

9.

Influenza viruses resistant to the antiviral drug oseltamivir: transmission studies in ferrets.

Herlocher ML, Truscon R, Elias S, Yen HL, Roberts NA, Ohmit SE, Monto AS.

J Infect Dis. 2004 Nov 1;190(9):1627-30. Epub 2004 Sep 28.

10.

Synthesis and anti-influenza evaluation of polyvalent sialidase inhibitors bearing 4-guanidino-Neu5Ac2en derivatives.

Masuda T, Yoshida S, Arai M, Kaneko S, Yamashita M, Honda T.

Chem Pharm Bull (Tokyo). 2003 Dec;51(12):1386-98.

11.

Optimization of tether length in nonglycosidically linked bivalent ligands that target sites 2 and 1 of a Shiga-like toxin.

Kitov PI, Shimizu H, Homans SW, Bundle DR.

J Am Chem Soc. 2003 Mar 19;125(11):3284-94.

PMID:
12630884
12.
13.

Novel alpha- and beta-amino acid inhibitors of influenza virus neuraminidase.

Kati WM, Montgomery D, Maring C, Stoll VS, Giranda V, Chen X, Laver WG, Kohlbrenner W, Norbeck DW.

Antimicrob Agents Chemother. 2001 Sep;45(9):2563-70.

14.

Synthesis and influenza virus sialidase inhibitory activity of analogues of 4-Guanidino-Neu5Ac2en (Zanamivir) modified in the glycerol side-chain.

Andrews DM, Cherry PC, Humber DC, Jones PS, Keeling SP, Martin PF, Shaw CD, Swanson S.

Eur J Med Chem. 1999 Jul-Aug;34(7-8):563-74.

PMID:
11278042
15.

Influenza chemotherapy: a review of the present state of art and of new drugs in development.

Lüscher-Mattli M.

Arch Virol. 2000;145(11):2233-48. Review.

PMID:
11205114
16.

The anti-influenza virus agent 4-GU-DANA (zanamivir) inhibits cell fusion mediated by human parainfluenza virus and influenza virus HA.

Greengard O, Poltoratskaia N, Leikina E, Zimmerberg J, Moscona A.

J Virol. 2000 Dec;74(23):11108-14.

17.
18.
20.

Plaque inhibition assay for drug susceptibility testing of influenza viruses.

Hayden FG, Cote KM, Douglas RG Jr.

Antimicrob Agents Chemother. 1980 May;17(5):865-70.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk